Business, energy, technology, markets and global industry news from Business News Today

Tiziana Life Sciences

Pharma & Biotech

Nasal foralumab reduces brain inflammation marker in Phase 2a multiple sclerosis trial

Tiziana Life Sciences' nasal foralumab meets Phase 2a multiple sclerosis endpoints. Explore brain inflammation, fatigue and safety findings.

Read More